University of Michigan researchers have made significant strides in understanding and treating a new, aggressive subtype of prostate cancer linked to the CDK12 gene. They’ve developed a mouse model to study the gene’s impact, discovered how its loss induces DNA damage, and created an innovative oral therapy that targets CDK12 and CDK13, showing promise in preliminary tests. This therapy, when combined with existing treatments, could potentially overcome the common problem of resistance in cancer treatment.